CA3181354A1 - Antagonists of the adenosine a2a receptor - Google Patents
Antagonists of the adenosine a2a receptorInfo
- Publication number
- CA3181354A1 CA3181354A1 CA3181354A CA3181354A CA3181354A1 CA 3181354 A1 CA3181354 A1 CA 3181354A1 CA 3181354 A CA3181354 A CA 3181354A CA 3181354 A CA3181354 A CA 3181354A CA 3181354 A1 CA3181354 A1 CA 3181354A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrazolo
- pyridy1
- chloro
- pyrimidin
- methy1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006823.5A GB202006823D0 (en) | 2020-05-07 | 2020-05-07 | Antagonist compounds |
| GB2006823.5 | 2020-05-07 | ||
| GB2019922.0 | 2020-12-16 | ||
| GBGB2019922.0A GB202019922D0 (en) | 2020-12-16 | 2020-12-16 | Antagonist compounds |
| PCT/GB2021/051106 WO2021224636A1 (en) | 2020-05-07 | 2021-05-06 | Antagonists of the adenosine a2a receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3181354A1 true CA3181354A1 (en) | 2021-11-11 |
Family
ID=75977772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3181354A Pending CA3181354A1 (en) | 2020-05-07 | 2021-05-06 | Antagonists of the adenosine a2a receptor |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4146654A1 (https=) |
| JP (2) | JP7724239B2 (https=) |
| KR (1) | KR20230035236A (https=) |
| CN (1) | CN115996929B (https=) |
| AU (1) | AU2021266433A1 (https=) |
| BR (1) | BR112022022437A2 (https=) |
| CA (1) | CA3181354A1 (https=) |
| CL (1) | CL2022003055A1 (https=) |
| CO (1) | CO2022017618A2 (https=) |
| EC (1) | ECSP22091613A (https=) |
| GB (1) | GB2609879B (https=) |
| IL (2) | IL297963A (https=) |
| MX (1) | MX2022013946A (https=) |
| PE (1) | PE20230769A1 (https=) |
| PH (1) | PH12022552987A1 (https=) |
| WO (1) | WO2021224636A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4447971A4 (en) * | 2021-12-17 | 2025-12-10 | Merck Sharp & Dohme Llc | PYRAZOLOPYRIMIDINE DERIVATIVES AND THEIR METHODS OF USE FOR THE TREATMENT OF HERPESVIRUS |
| CN116283994B (zh) * | 2021-12-20 | 2025-01-07 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的杂环化合物 |
| CN117247386B (zh) * | 2022-01-18 | 2025-10-24 | 江苏亚尧生物科技有限公司 | 新型吡唑并嘧啶化合物及其组合物、制备方法和用途 |
| JP2025512384A (ja) * | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2025094087A1 (en) | 2023-10-30 | 2025-05-08 | Johnson & Johnson Enterprise Innovation Inc. | Safe administration of a2a rector antagonist |
| WO2025123251A1 (en) | 2023-12-13 | 2025-06-19 | Johnson & Johnson Enterprise Innovation Inc. | Crystalline forms of a2a receptor antagonist, preparation methods, and uses thereof |
| WO2025123253A1 (en) | 2023-12-13 | 2025-06-19 | Johnson & Johnson Enterprise Innovation Inc. | Pharmaceutical compositions of an a2a receptor antagonist |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025202955A1 (en) | 2024-03-28 | 2025-10-02 | Pi Industries Ltd. | Fused bicyclic compounds and their use as pest control agents |
| CN120093763A (zh) * | 2025-03-25 | 2025-06-06 | 上海天龙生物科技有限公司 | 治疗前列腺疾病和腺体类散结节的药物组合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3910907A (en) * | 1973-07-09 | 1975-10-07 | Icn Pharmaceuticals | Pyrazolo(1,5-a)-1,3,5-triazines |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| US7662826B2 (en) * | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
| US8178533B2 (en) * | 2005-06-01 | 2012-05-15 | Ucb Pharma, S.A. | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| CN101686989B (zh) * | 2007-06-21 | 2016-10-19 | 卡拉治疗学股份有限公司 | 取代的咪唑并杂环 |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| EP2402337A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
| EP2402343A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole-fused bicyclic compounds |
| EP2402344A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| EP2402345A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| WO2012100342A1 (en) * | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| ES2728932T3 (es) * | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| CA2969265A1 (en) * | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| WO2017178844A1 (en) * | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| US11608334B2 (en) * | 2017-02-08 | 2023-03-21 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
-
2021
- 2021-05-06 EP EP21726445.6A patent/EP4146654A1/en active Pending
- 2021-05-06 GB GB2217519.4A patent/GB2609879B/en active Active
- 2021-05-06 JP JP2022567895A patent/JP7724239B2/ja active Active
- 2021-05-06 WO PCT/GB2021/051106 patent/WO2021224636A1/en not_active Ceased
- 2021-05-06 AU AU2021266433A patent/AU2021266433A1/en active Pending
- 2021-05-06 CA CA3181354A patent/CA3181354A1/en active Pending
- 2021-05-06 BR BR112022022437A patent/BR112022022437A2/pt unknown
- 2021-05-06 IL IL297963A patent/IL297963A/en unknown
- 2021-05-06 KR KR1020227042714A patent/KR20230035236A/ko active Pending
- 2021-05-06 CN CN202180047824.2A patent/CN115996929B/zh active Active
- 2021-05-06 PH PH1/2022/552987A patent/PH12022552987A1/en unknown
- 2021-05-06 MX MX2022013946A patent/MX2022013946A/es unknown
- 2021-05-06 PE PE2022002570A patent/PE20230769A1/es unknown
-
2022
- 2022-11-04 CL CL2022003055A patent/CL2022003055A1/es unknown
- 2022-12-01 EC ECSENADI202291613A patent/ECSP22091613A/es unknown
- 2022-12-06 CO CONC2022/0017618A patent/CO2022017618A2/es unknown
-
2025
- 2025-08-04 JP JP2025130117A patent/JP2025183201A/ja active Pending
- 2025-10-19 IL IL324071A patent/IL324071A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230035236A (ko) | 2023-03-13 |
| CO2022017618A2 (es) | 2023-02-16 |
| EP4146654A1 (en) | 2023-03-15 |
| MX2022013946A (es) | 2023-02-01 |
| ECSP22091613A (es) | 2023-03-31 |
| GB2609879A (en) | 2023-02-15 |
| GB202217519D0 (en) | 2023-01-04 |
| WO2021224636A1 (en) | 2021-11-11 |
| IL297963A (en) | 2023-01-01 |
| PE20230769A1 (es) | 2023-05-09 |
| AU2021266433A1 (en) | 2022-12-15 |
| CN115996929A (zh) | 2023-04-21 |
| JP7724239B2 (ja) | 2025-08-15 |
| IL324071A (en) | 2025-12-01 |
| PH12022552987A1 (en) | 2024-02-26 |
| CL2022003055A1 (es) | 2023-07-07 |
| JP2023525762A (ja) | 2023-06-19 |
| BR112022022437A2 (pt) | 2023-01-03 |
| US20230203041A1 (en) | 2023-06-29 |
| GB2609879B (en) | 2023-08-16 |
| CN115996929B (zh) | 2026-01-13 |
| JP2025183201A (ja) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7724239B2 (ja) | アデノシンａ２ａ受容体のアンタゴニスト | |
| EP4188924B1 (en) | Antagonist compounds | |
| WO2022090711A1 (en) | Compounds as cd73 inhibitors | |
| WO2022123272A1 (en) | Antagonists of the adenosine a2a receptor | |
| US12617796B2 (en) | Antagonists of the adenosine A2a receptor | |
| HK40130881A (en) | Antagonist compounds | |
| AU2023210919A1 (en) | Antagonist of adenosine receptors | |
| WO2023233130A1 (en) | Cd73 inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241104 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250417 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250417 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250616 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250616 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250709 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260407 |